BIOMERICA INC (BMRA) Form 8-K — Jun 4, 2026
Biomerica, Inc. (BMRA) entered into a Securities Purchase Agreement on May 29, 2026, to sell its 78,750 shares of Diagnosis S.A., representing approximately 6% of the Polish medical products company, for an aggregate price of $500,000. The buyers are entities and individuals affiliated with Biomerica’s CEO, Zackary Irani. The transaction is structured as a secured promissory note with an 8% interest rate, maturing in 12 months, which will be largely forgiven upon the successful transfer of the shares, leaving Biomerica to pay only a nominal 60-day interest fee.
Key figures
- Debt Amount
- 500000
- Deal Value Usd
- 500000
- Interest Rate
- 8
- Maturity Date
- 2027-05-29
- Offering Price
- 6.3492
- Shares Offered
- 78750
- Dividend received
- 52000
- Minimum interest payment
- 60 days of interest on $500k at 8%
- Forgivable note principal
- 500000
Price after filing
Close on the filing date to close N calendar days later (from $2.15). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.